Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2005

View Archived Issues

DA-8159 as a treatment for diabetic erectile dysfunction

CC-4047's mechanism of action remains unclear

NexBio presents Fludase, a novel antiinfluenza recombinant fusion protein / News in Context

Two liposomal lurtotecan regimens induce antitumor effects in relapsed ovarian cancer

CEP-8983 chemosensitizes resistant cells and xenografts

BTS-2 inhibitory activity depends on redox state of tNOX

APF-530 enters phase II for CINV in cancer patients

ISTA seeks green light for phase III trial of combination ophthalmic product

ZLB Behring to study C1-INH concentrate for hereditary angioedema

Inspire reports ophthalmic programs update

Mitsubishi Chemical and Mitsubishi Pharma to form joint holding company

Phase I cancer study of CYT-997 set to begin in May

Prism to market Penwest's PW-2101 in U.S., Canada

Vical's bivalent CMV vaccine set for phase II

ISIS-369645 enters development for asthma

New treatments for cancer covered in recent patents

AS-1410 selected for phase I evaluation against cancer

Complete tumor regression in mice treated with huC242-DM4

First, highly selective 5-HT1D antagonist reported

Novel antihypertensive agents discovered at Bristol-Myers Squibb

Santarus reports new formulations of omeprazole for treating acid-induced gastrointestinal disorders

New antidiabetic agents from Ligand and Takeda

Phase I data confirm MVA-3000 vaccine is safe and immunogenic in healthy volunteers

Evidence suggests a link between sleep disorders and metabolic syndrome in mice

UNBS-1450 demonstrates in vitro and in vivo anticancer activity